Clinical Trial Update: Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase II trial of copanlisib in relapsed/refractory diffuse large B-cell lymphoma has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Copanlisib (copanlisib)

Snippet

Sponsor: Bayer | Conditions: Diffuse, Large B-Cell, Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-01-08